Título : |
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update |
Tipo de documento : |
documento electrónico |
Autores : |
Luis Vicente Syro Moreno, |
Fecha de publicación : |
2018 |
Títulos uniformes : |
Endocrine Related Cancer
|
Idioma : |
Inglés (eng) |
Palabras clave : |
Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide |
Resumen : |
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. |
Mención de responsabilidad : |
Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs |
Referencia : |
Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. |
DOI (Digital Object Identifier) : |
10.1530/ERC-18-0015 |
PMID : |
29535142 |
En línea : |
https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 |
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno, . - 2018. Obra : Endocrine Related CancerIdioma : Inglés ( eng) Palabras clave : |
Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide |
Resumen : |
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. |
Mención de responsabilidad : |
Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs |
Referencia : |
Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. |
DOI (Digital Object Identifier) : |
10.1530/ERC-18-0015 |
PMID : |
29535142 |
En línea : |
https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 |
| |